Hibbert Briefings
Weekly briefings on what moved in medicine last week: the evidence, what clinicians are saying, and what changes in practice. A sibling to the Seminar Series.
- Serotonin: what the new evidence changes (Evidence, week of 2026-09-07) — Inhaled mebufotenin and synthetic psilocybin show large, rapid effects in treatment-resistant depression, but both remain investigational. Memantine augmentation emerges for severe OCD, while the serotonin hypothesis debate continues.
- ACA subsidies: what clinicians need to know while it is in the news (In the news, week of 2026-09-07) — Enhanced ACA premium tax credits expired in January 2026, driving a 13% enrollment drop, 58% premium increase, and record-high deductibles. Clinicians should screen for coverage loss and financial barriers at every visit.
- ESC Munich 2026: the results that change practice (Evidence, week of 2026-08-31) — ESC Munich 2026 delivered practice-changing evidence: simplified HF phenotypes, a new MI classification, catheter-directed thrombolysis for PE, and prasugrel's bleeding advantage over ticagrelor.
- Postpartum psychosis: what clinicians need to know while it is in the news (In the news, week of 2026-08-31) — Postpartum psychosis affects 1–2 per 1000 births, typically within two weeks of delivery. Women with bipolar disorder or prior postpartum psychosis face roughly a one-in-three risk of postpartum relapse; prophylactic lithium or antipsychotic medication started immediately after delivery reduces rel…
- Migraine prevention: what the new guideline changes (Guideline, week of 2026-08-31) — The joint AAN/AHS guideline recommends preventive therapy at ≥4 migraine days per month and positions CGRP monoclonal antibodies alongside traditional oral agents as initial options, without requiring prior treatment failures.
- Measles death: what clinicians need to know while it is in the news (In the news, week of 2026-08-31) — The US measles surge has reached 3,134 cases—the highest in 35 years—with renewed focus on deaths and complications in unvaccinated populations.